Korean molecular diagnostic company Gencurix Inc reported on Wednesday that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its GenePro SARS-CoV-2 Test, a diagnostic kit for COVID-19.
This is the second RT-PCR test launched by Gencurix following its first test assay, GenePro COVID-19 Detection Test, which was released in March.
Advantages of the GenePro SARS-CoV-2 Test include simultaneous monitoring of up to 384 samples, allowing high throughput screening of the novel coronavirus.
With the FDA's EUA, Gencurix is now able to provide its COVID-19 detection tests across the United States.
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin